FI57761C - Foerfarande foer framstaellning av antiinflammatoriskt vattenloesligt injicerbart tvaerbundet orgotein - Google Patents
Foerfarande foer framstaellning av antiinflammatoriskt vattenloesligt injicerbart tvaerbundet orgotein Download PDFInfo
- Publication number
- FI57761C FI57761C FI762567A FI762567A FI57761C FI 57761 C FI57761 C FI 57761C FI 762567 A FI762567 A FI 762567A FI 762567 A FI762567 A FI 762567A FI 57761 C FI57761 C FI 57761C
- Authority
- FI
- Finland
- Prior art keywords
- orgotein
- crosslinked
- protein
- organotein
- vtenloesligt
- Prior art date
Links
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 title description 52
- 108010070915 orgotein Proteins 0.000 title description 51
- 229960004534 orgotein Drugs 0.000 title description 49
- 102000004169 proteins and genes Human genes 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004132 cross linking Methods 0.000 description 9
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005227 gel permeation chromatography Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000003431 cross linking reagent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- LEOJDCQCOZOLTQ-UHFFFAOYSA-N dibutylcarbamothioyl n,n-dibutylcarbamodithioate Chemical compound CCCCN(CCCC)C(=S)SC(=S)N(CCCC)CCCC LEOJDCQCOZOLTQ-UHFFFAOYSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- ILKCDNKCNSNFMP-UHFFFAOYSA-N dimethyl octanediimidate;hydron;dichloride Chemical compound Cl.Cl.COC(=N)CCCCCCC(=N)OC ILKCDNKCNSNFMP-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 108010058237 plasma protein fraction Proteins 0.000 description 2
- 229940081857 plasma protein fraction Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- AKVAGWOVWQDTAF-UHFFFAOYSA-N 1-bromo-4-(1-isocyanatoethyl)benzene Chemical compound O=C=NC(C)C1=CC=C(Br)C=C1 AKVAGWOVWQDTAF-UHFFFAOYSA-N 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
- DASMEZATWQCXPC-UHFFFAOYSA-N dimethyl octanediimidate;hydrochloride Chemical compound Cl.COC(=N)CCCCCCC(=N)OC DASMEZATWQCXPC-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- -1 glutaraldehyde orgotein derivatives Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61165875 | 1975-09-09 | ||
| US05/611,658 US4009267A (en) | 1975-09-09 | 1975-09-09 | Cross-linked orgotein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI762567A FI762567A (xx) | 1977-03-10 |
| FI57761B FI57761B (fi) | 1980-06-30 |
| FI57761C true FI57761C (fi) | 1980-10-10 |
Family
ID=24449918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI762567A FI57761C (fi) | 1975-09-09 | 1976-09-07 | Foerfarande foer framstaellning av antiinflammatoriskt vattenloesligt injicerbart tvaerbundet orgotein |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4009267A (xx) |
| JP (1) | JPS5233980A (xx) |
| AT (1) | AT349034B (xx) |
| BE (1) | BE845542A (xx) |
| CA (1) | CA1059911A (xx) |
| CS (1) | CS205040B2 (xx) |
| DD (1) | DD128696A5 (xx) |
| DE (1) | DE2637779A1 (xx) |
| DK (1) | DK396476A (xx) |
| FI (1) | FI57761C (xx) |
| FR (1) | FR2323396A1 (xx) |
| GB (1) | GB1514049A (xx) |
| IE (1) | IE43719B1 (xx) |
| IL (1) | IL50288A (xx) |
| NL (1) | NL7609878A (xx) |
| NO (1) | NO763076L (xx) |
| SE (1) | SE7609979L (xx) |
| ZA (1) | ZA765348B (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2449885C3 (de) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
| IL47468A (en) * | 1975-06-12 | 1979-05-31 | Rehovot Res Prod | Process for the cross-linking of proteins using water soluble cross-linking agents |
| CA1146581A (en) * | 1977-12-16 | 1983-05-17 | Pieter A. Verbrugge | Intermediates in the preparation of cyclopropylcarboxylate esters and process for their manufacture |
| US4199502A (en) * | 1978-08-04 | 1980-04-22 | Warner-Lambert Company | Removal of heparin from blood plasma samples using an insoluble protamine reaction product |
| US4473495A (en) * | 1983-07-28 | 1984-09-25 | Northwestern University | Albumin-solubilized hymenoptera venoms for vaccine use |
| US20030069174A1 (en) * | 1997-03-10 | 2003-04-10 | Ludwig Pichler | Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687927A (en) * | 1971-06-07 | 1972-08-29 | Diagnostic Data Inc | Orgotein isolation process employing single ion exchange resin having both acidic and basic groups |
| US3758682A (en) * | 1972-03-23 | 1973-09-11 | Diagnostics Data Inc | Pharmaceutical compositions comprising orgotein and their use |
| US3813289A (en) * | 1972-07-19 | 1974-05-28 | Diagnostic Data Inc | Orgotein from red blood cells |
| US3925344A (en) * | 1973-04-11 | 1975-12-09 | Community Blood Council | Plasma protein substitute |
-
1975
- 1975-09-09 US US05/611,658 patent/US4009267A/en not_active Expired - Lifetime
-
1976
- 1976-08-17 IL IL50288A patent/IL50288A/xx unknown
- 1976-08-20 FR FR7625355A patent/FR2323396A1/fr active Granted
- 1976-08-21 DE DE19762637779 patent/DE2637779A1/de not_active Ceased
- 1976-08-26 AT AT635976A patent/AT349034B/de not_active IP Right Cessation
- 1976-08-26 BE BE170097A patent/BE845542A/xx unknown
- 1976-09-02 DK DK396476A patent/DK396476A/da not_active Application Discontinuation
- 1976-09-06 NL NL7609878A patent/NL7609878A/xx not_active Application Discontinuation
- 1976-09-07 FI FI762567A patent/FI57761C/fi not_active IP Right Cessation
- 1976-09-07 DD DD7600194661A patent/DD128696A5/xx unknown
- 1976-09-07 CA CA260,687A patent/CA1059911A/en not_active Expired
- 1976-09-08 ZA ZA765348A patent/ZA765348B/xx unknown
- 1976-09-08 IE IE2000/76A patent/IE43719B1/en unknown
- 1976-09-08 NO NO763076A patent/NO763076L/no unknown
- 1976-09-09 JP JP51108655A patent/JPS5233980A/ja active Pending
- 1976-09-09 GB GB37430/76A patent/GB1514049A/en not_active Expired
- 1976-09-09 SE SE7609979A patent/SE7609979L/xx not_active Application Discontinuation
- 1976-09-09 CS CS765858A patent/CS205040B2/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5233980A (en) | 1977-03-15 |
| DD128696A5 (de) | 1977-12-07 |
| IE43719B1 (en) | 1981-05-06 |
| FI762567A (xx) | 1977-03-10 |
| FR2323396B1 (xx) | 1979-09-28 |
| NO763076L (xx) | 1977-03-10 |
| US4009267A (en) | 1977-02-22 |
| AT349034B (de) | 1979-03-12 |
| FR2323396A1 (fr) | 1977-04-08 |
| BE845542A (fr) | 1977-02-28 |
| IE43719L (en) | 1977-03-09 |
| SE7609979L (sv) | 1977-03-10 |
| CS205040B2 (en) | 1981-04-30 |
| GB1514049A (en) | 1978-06-14 |
| NL7609878A (nl) | 1977-03-11 |
| DE2637779A1 (de) | 1977-03-17 |
| IL50288A (en) | 1979-09-30 |
| FI57761B (fi) | 1980-06-30 |
| CA1059911A (en) | 1979-08-07 |
| ZA765348B (en) | 1977-09-28 |
| ATA635976A (de) | 1978-08-15 |
| DK396476A (da) | 1977-03-10 |
| IL50288A0 (en) | 1976-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5750725A (en) | Hemoglobin crosslinkers | |
| DK166966B1 (da) | Analogifremgangsmaade til fremstilling af immunoenzymatiske konjugater | |
| Boccu et al. | Pharmacokinetic properties of polyethylene glycol derivatized superoxide dismutase | |
| EP0162332B1 (en) | Preparation containing stabilized polypeptide having gamma-interferon activity | |
| Carter et al. | Testosterone-induced, sulfonamide-resistant carbonic anhydrase isozyme of rat liver is indistinguishable from skeletal muscle carbonic anhydrase III | |
| US7501499B2 (en) | Modified hemoglobin and methods of making same | |
| MX2011013215A (es) | Composiciones de hemoglobina. | |
| Gonias et al. | Effects of diethyldithiocarbamate and nine other nucleophiles on the intersubunit protein cross-linking and inactivation of purified human α2-macroglobulin by cis-diamminedichloroplatinum (II) | |
| FI57761C (fi) | Foerfarande foer framstaellning av antiinflammatoriskt vattenloesligt injicerbart tvaerbundet orgotein | |
| Tsuyuki et al. | The preparation and physical properties of polypeptidyl proteins1, 2 | |
| PL99599B1 (pl) | Sposob otrzymywania tolerowanej srodzylnie gammaglobuliny | |
| Caccia et al. | PEGylation promotes hemoglobin tetramer dissociation | |
| ES2395894T3 (es) | Hemoglobinas de mamífero compatibles con plasma sanguíneo, reticuladas y conjugadas con poli(óxidos de alquileno) como portadores de oxígeno médicos artificiales, su preparación y su uso | |
| JP2001081103A (ja) | ヒアルロン酸結合薬剤 | |
| EP0025321A2 (en) | Composition containing S-sulfonated immunoglobulin and aggregation preventing or aggregate dissociating agent therefor, and processes for preparing compositions containing high proportions of monomeric S-sulfonated immunoglobulin | |
| Kojima et al. | Conjugation of copper-zinc superoxide dismutase with succinylated gelatin: Pharmacological activity and cell-lubricating function | |
| US6555656B2 (en) | Covalent modification of abnormal prion protein | |
| Klausner et al. | The folding of ovalbumin. Renaturation in vitro versus biosynthesis in vitro | |
| Deshmukh | A comparative study of the crosslinking precursors present in rat skin and tail tendon collagen | |
| RU2176517C2 (ru) | Комплекс природных катионных белков и способ его получения | |
| JPS60226819A (ja) | フイブロネクチン複合体 | |
| EP0314749A1 (en) | HEMOGLOBIN COMPLEXES. | |
| Sela et al. | [50] Reaction with N-carboxy-α-amino acid anhydrides | |
| US20080306245A1 (en) | Method For The Production Of Albumen Conjugates With Non-Steroidal Antirheumatic Drugs (Nsar) | |
| Veronese et al. | Superoxide dismutase modifications for anti-inflammatory therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: DIAGNOSTIC DATA, INC. |